New Anti-Clotting Medication Reduces Stroke Risk Without Increasing Bleeding: Breakthrough Findings from Recent Studies

A new anti-clotting medication, asundexian, has demonstrated a significant reduction in the risk of recurrent stroke without increasing the risk of bleeding, according to results from a major international clinical trial presented in April 2026.

The findings come from the OCEANIC-STROKE phase III trial, which evaluated asundexian in patients who had previously experienced a non-cardioembolic stroke or transient ischemic attack (TIA). Researchers found that participants taking asundexian at a dose of 50 mg once daily, in addition to standard antiplatelet therapy such as aspirin, had a 26% lower risk of experiencing another ischemic stroke compared to those receiving a placebo.

Specifically, 6.2% of patients in the asundexian group (382 out of 6,162) suffered a recurrent stroke, compared to 8.4% in the placebo group (518 out of 6,165). The trial also showed a 17% reduction in major cardiovascular events, which include stroke, heart attack, or cardiovascular death, with 9.2% of the asundexian group experiencing such events versus 11% in the placebo group.

Importantly, the study found no increase in the risk of major bleeding among patients taking asundexian. This addresses a key limitation of existing anticoagulant therapies, which often carry a heightened risk of hemorrhage while preventing clots.

Asundexian works by inhibiting activated factor XI (FXI), a protein involved in the blood coagulation pathway. Unlike traditional anticoagulants that target multiple clotting factors and can disrupt hemostasis, FXI inhibition appears to selectively reduce pathological clot formation while preserving normal bleeding control.

The trial included 12,327 adult patients from 37 countries, with treatment initiated within 72 hours of the initial stroke or TIA event. Participants were followed for up to 31 months, with assessments conducted at one month and then every three months thereafter.

Researchers emphasized that while the results are promising, the findings are based on a single trial and require further validation. The study was sponsored by Bayer, and asundexian remains an investigational agent not yet approved for general use.

The OCEANIC-STROKE trial results were published in the New England Journal of Medicine on April 15, 2026, and were previously presented as late-breaking science at the American Stroke Association’s International Stroke Conference in February 2026.

Experts note that if confirmed in additional studies, asundexian could offer a safer alternative for long-term secondary stroke prevention, particularly for patients at high risk of recurrence who may not tolerate current therapies due to bleeding concerns.